XML 15 R2.htm IDEA: XBRL DOCUMENT v3.23.2
Condensed Consolidated Balance Sheets - USD ($)
Jun. 30, 2023
Dec. 31, 2022
Current assets:    
Cash and cash equivalents $ 52,712,543 $ 46,329,359
Short-term investments 142,212,907 206,669,397
Prepaid expenses and other current assets 3,230,882 50,130,481
Prepaid expenses and other current assets from affiliated entities 11,928 375,227
Total current assets 203,284,486 315,242,680
Fixed assets, net 6,303,949 7,727,997
Investment in affiliated entity 2,780,526 2,007,142
Intangible assets, net 0 2,129,861
Goodwill 10,513,371 10,513,371
Operating lease right-of-use assets 9,488,738 10,228,207
Other assets 666,890 684,044
Total assets 233,037,960 348,533,302
Current liabilities:    
Accrued clinical trial expenses 6,172,382 10,594,073
Operating lease liability 2,351,449 2,803,973
Grant funding liability 3,704,781 2,475,031
Grant funding liability from affiliated entity 43,836 87,673
Convertible senior notes 16,708,329 0
Total current liabilities 51,932,302 96,868,074
Convertible senior notes 0 16,614,840
Operating lease liability, net of current portion 11,702,044 12,655,586
Deferred tax liabilities 32,046 32,046
Total liabilities 63,666,392 126,170,546
Stockholders’ equity:    
Preferred stock 0 0
Common stock 268,072 253,090
Additional paid-in capital 1,733,826,392 1,710,656,191
Accumulated deficit (1,564,031,634) (1,487,847,784)
Accumulated other comprehensive loss (691,262) (698,741)
Total Inovio Pharmaceuticals, Inc. stockholders’ equity 169,371,568 222,362,756
Total liabilities and stockholders’ equity 233,037,960 348,533,302
Nonrelated Party    
Current assets:    
Accounts receivable 5,947 1,701,726
Current liabilities:    
Accounts payable and accrued expenses 21,265,150 79,686,885
Related Party    
Current assets:    
Accounts receivable 5,110,279 10,036,490
Current liabilities:    
Accounts payable and accrued expenses $ 1,686,375 $ 1,220,439